Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-07-21

EMA Authorised: Eltrombopag Accord (eltrombopag olamine) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA authorises Eltrombopag Accord for idiopathic thrombocytopenic purpura (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eltrombopag Accord (eltrombopag olamine)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic. MAH: Accord Healthcare S.L.U.. Decision date: 10/10/2025